Newsroom

SINGAPORE--(BUSINESS WIRE)--KAYTUS Completes 100-Cabinet Liquid-Cooled Data Center in Europe in Four Months...

NORWICH, England & CHICAGO--(BUSINESS WIRE)--Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD). Following successful further evaluation of the t...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST. 44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation Date: Wednesda...

PARIS--(BUSINESS WIRE)--  In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from December 29 to December 30, 2025: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Am...

PARIS--(BUSINESS WIRE)--Regulatory News :  Etablissements Maurel & Prom S.A. (« M&P », le « Groupe ») (Paris:MAU) annonce que, suite à son communiqué de presse du 29 décembre 2025 relatif à l’approbation délivrée par l’Agence Nationale des Hydrocarbures colombienne (« ANH »), les transactions précédemment annoncées concernant l’acquisition par M&P d’une participation totale de 61% et du rôle d’opérateur dans la licence gazière Sinu-9 en Colombie ont été finalisées avec succès le lun...

PARIS--(BUSINESS WIRE)--Regulatory News: Etablissements Maurel & Prom S.A. (“M&P”, the “Group”) (Paris:MAU) announces that, further to its press release dated 29 December 2025 regarding the approval granted by Colombia’s National Hydrocarbons Agency (ANH), the transactions previously announced relating to the acquisition by M&P of a total 61% working interest and operatorship in the Sinu-9 gas licence in Colombia were successfully closed on Monday 5 January 2026. The transactions co...

PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from December 29 to December 30, 2025: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares...

PARIS--(BUSINESS WIRE)--Regulatory News: Dans le cadre des autorisations consenties par l’Assemblée générale du 23 mai 2025 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d'actions, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI : 529900S21EQ1BO4ESM68) déclare ci-après les achats d’actions propres (FR0000120271) réalisés du 29 décembre au 30 décembre 2025 : Jour de la transaction Volume total journalier (en nombre de titres) Prix pondéré moyen journ...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 5 January 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 5 January 2026 Number of Public Shares Purchased: 18,3...

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of early analyses of activity in patients with oesophageal cancer during its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+ solid tumours, at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, US (8-10 January). The Phase 1 study (NCT05872295)...